Kadmon Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference

(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 01/07/15 -- Kadmon Corporation, LLC, today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 7:30 a.m. PT at the Westin St. Francis in San Francisco, CA. Dr. Waksal will provide an overview of Kadmon and its clinical and commercial programs.

Kadmon Corporation, LLC, is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in oncology, autoimmune and fibrotic diseases, monogenic diseases and metabolic disease. For more information, visit .

This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.



Ellen Tremaine
Investors
646.490.2989


David Pitts
Argot Partners
212.600.1902

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 07.01.2015 - 14:30 Uhr
Sprache: Deutsch
News-ID 362894
Anzahl Zeichen: 0

contact information:
Town:

NEW YORK, NY

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 236 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Kadmon Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Kadmon Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Kadmon Issues Statement on Rosenfeld Lawsuit ...

NEW YORK, NY -- (Marketwired) -- 06/23/16 -- Kadmon Corporation, LLC today issued the following statement in response to a press release issued on June 22, 2016 from counsel for plaintiff Steven Rosenfeld, regarding the action he commenced on Februa ...

Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Idiopathic Pulmonary ...

NEW YORK, NY -- (Marketwired) -- 06/03/16 -- Kadmon Corporation, LLC today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company's rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatm ...

Kadmon to Present Preclinical Data Demonstrating That Its Novel Immuno-Oncology ...

NEW YORK, NY -- (Marketwired) -- 04/14/16 -- Kadmon Corporation, LLC today announced the presentation of new preclinical data demonstrating that its novel anti-PD-L1/IL-15 bi-functional fusion protein, KD033, stimulated long-lasting and persistent a ...

Alle Meldungen von Kadmon Corporation